详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Pharmacokinetics, Efficacy and Safety of the 304 Injection

3| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. [2]Beijing Luhe Hospital Capital Medical University Beijing, Beijing, China, 101100 [3]Sun Yat-Sen University Cancer Hospital Guangzhou, Guangdong, China, 510600 [4]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050010 [5]Affiliated Hospital of Hebei University Baoding, Heibei, China, 071000 [6]Zhengzhou Central Hospital Zhengzhou, Henan, China, 450007 [7]The First Affiliated Hospita of Zhengzhou University Zhengzhou, Henan, China, 450052 [8]Weihai Municipal Hospital Weihai, Shandong, China, 264200 [9]Tianjin Medical University Cancer Institute &Hospital Tianjing, Tianjing, China, 300060 [10]The Second Affiliated Hospital of Soochow University Suzhou, Zhejiang, China, 215000 [11]The 307 Hospital of People's Liberation Army Beijing, Beijing, China, 100071

研究目的：

The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304 injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin lymphoma who had previously achieved CR/CRu status but had not deteriorated or relapsed. While to assess the safety and efficacy of the experimental drug 304 injection compared with rituximab injection.